Follow Us:Respiratio 2019; 9 (1-2): 30-35
DA LI JE HISTOLOŠKA GRAĐA ADENOKARCINOMA PLUĆA U
DIJAGNOSTIČKIM I TERAPIJSKIM UZORCIMA IDENTIČNA?
Tegeltija Dragana, Lovrenski Aleksandra, Vasiljević Tijana, Vanesa Sekeruš, Maksimović
Siniša, Kuhajda Ivan, Bijelović Milorad, Ivanić Milena, Miroslav Ilić
Original research
Naučni članak
Apstrakt
Uvod: Adenokarcinom (ADC) pluća ima heterogenu histološku građu. Dijagnostički uzorak (DU)
može da bude citološki ili histološki, najčešće se dobija bronhoskopijom. Kompletna hirurška resekcija
tumora predstavlja jedan od oblika lečenja obolelih od ADC.
Materijal i metode:U istraživanje je bilo uključeno 143 bolesnika sa dijagnostikovanim i hirurški
lečenim ADC pluća od 2010. do 2015. na Institutu za plućne bolesti Vojvodine. Analizirani podaci su
preuzeti iz istorije bolesti. Svi uzorci su reklasifikovani na osnovu kriterijuma SZO iz 2015. DU i
terapijski uzorak (TU) sa jednim histološkim aranžmanom smo smatrali homogenim (Ho), heterogeni
(He) su bili uzorci sa dva ili više aranžmana.
Rezultati:U istraživanje je bilo uključeno 84 muškaraca i 59 žena, 94 (66%) pušača, prosečne
starosti od 66 godina. DU su u 76% slučajeva dobijeni bronhobiopsijom i najčešće su bili Ho (69%). TU
dobijeni nakon lobektomije su bili najzastupljeniji (80%), najčešće He (75%). Acinarni i solidni
histološki tip je bio najzastupljeniji u obe grupe uzoraka.
Cilj rada je bio da se utvrdi da li je histološka građa adenokarcinoma pluća u dijagnostičkim i
terapijskim uzorcima identična.
Zaključak:Iako postoji statistički značajna razlika između histološke građe ADC u TU i DU
(p<0,001) acinarni tip je najzastupljeniji histološki tip (p=0,65883) uz podudaranje histoloških tipova
kod 106/143 (74%) bolesnika.
Ključne reči:Adenokarcinom, bronhobiopsija, hirurška terapija, histološka građa.
Literatura
|
1. Adler I. Primary malignant growths of the lungs and bronchi. New York: Longmans, Green; 1912. |
|
|
|
|
|
2. International Agency for Research on Cancer: GLOBOCAN 2012; Estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer, Lyon, France 2012. Available from: http://globocan.iarc.fr Accessed February 12, 2013. |
|
|
|
|
|
3. Henley JS, Richards TB, Underwood MJ, Eheman CR, Plescia M, Timothy A, et al. Lung cancer incidence trends among men and women United States,2005-2009. MMWR.2014 Jan 10;63(1):1-5. |
|
|
|
|
|
4. El-Basmy A. Profile of lung cancer in Kuwait. Asian Pac J Cancer Prev. 2013;14(10):6181-4. [CrossRef] |
|
|
|
|
|
5. Lewis DR, Chen HS Lewis DR, Chen HS, Feurer EJ. SEER Cancer statistics review, 1975-2008. Bethesda, MD National Cancer Institute; 2010. Available from:http://seer.cancer.gov/csr/1975_2010/. Accessed October 20, 2013. |
|
|
|
|
|
6. Hajmanoochehri F, Mohammadi N, Zohal MA, Sodagar A, Ebtehaj M. Epidemiological and clinicopathological characteristics of lung cancer in a teaching hospital in Iran. Asian Pac J Cancer Prev. 2014;15(6):2495-500. [CrossRef] |
|
|
|
|
|
7. Suda K, Sato K, Shimizu S, Tomizawa K, Takemoto T, Iwasaki T, et al. Prognostic implication of predominant histologic subtypes of lymph node metastases in surgically resected lung adenocarcinoma. BioMed Res Int. 2014;2014:645-81. [CrossRef] |
|
|
|
|
|
8. Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol. 2013 Apr;8(4):461-8. [CrossRef] |
|
|
|
|
|
9. Furukawa M, Toyooka S, Ichimura K, Yamamoto H, Soh J, Hashida S, et al. Genetic alterations in lung adenocarcinoma with a micropapillary component. Mol Clin Oncol. 2016;4(2):195-200. [CrossRef] |
|
|
|
|
|
10. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6(2):244-85. [CrossRef] |
|
|
|
|
|
11. Prudence R, Zoe W, Gavin W, Marissa D, Matthew C, Richard W. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. Thorac Oncol. 2011Sep;6(9):1496-504. [CrossRef] |
|
|
|
|
|
12. Yoshizawa A, Motoi N, Riely G, Sima CS, Gerald WL, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011. May;24(5):653-64. [CrossRef] |
|
|
|
|
|
13. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300.,
|
|
|
|
|
|
14. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol. 2012;23(4):1044-52. [CrossRef] |
|
|
|
|
|
15. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013 Jan;8(1):52- 61. [CrossRef] |
|
|
|
|
|
16. Stojšić J, Adzić T, Marić D, Subotić D, Milovanović I, Milenković B, et al. Histological types and age distribution of lung cancer operated patients over a 20-year period: a pathohistological based study. Srp Arh Celok Lek. 2011 Sep-Oct;139(9-10):619-24. [CrossRef] |
|
|
|
|
|
17. Paliogiannis P, Attene F, Cossu A, Defraia E, Porcu G, Carta A, et al. Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma. Mol Med Rep. 2015 Jul;12(1):187-91. [CrossRef] |
|
|
|
|
|
18. Zhu P, Pan Q, Wang M. Efficacy of bronchoscopic biopsy for the detection of epidermal growth factor receptor mutations and anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma. Thorac Cancer. 2015 Nov;6(6):709-14. [CrossRef] |
|
|
|
|
|
19. Balaban G, Žikić T, Perin B, Čanak V, Kopitović I, Jovanović S. Operabilnost bolesnika sa centralnim karcinomom bronha i atelektazom. Pneumon. 1998;36(1-4):11-4. |
|
|
|
|
|
20. Wang S, Yu B, Chiu Chin Ng, Mercorella B, Selinger CI, O'Toole SA, et al. The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. Trans Lung Cancer Res. 2015 April; 4(2):119-25. |
|
|
|
|
|
21. Gellert AR, Rudd RM, Sinha G, Geddes DM. Fiberoptic bronchoscopy: effect of multiple bronchial biopsies on diagnostic yield in bronchial carcinoma. Thorax. 1982 Sep;37(9):684-7. [CrossRef] |
|
|
|
|
|
22. Coghlin CL, Smith LJ, Bakar S, Stewart KN, Devereux GS, Nicolson MC, et al. Quantitative analysis of tumor in bronchial biopsy specimens. J Thorac Oncol. 2010 Apr;5(4):448-52. [CrossRef] |
|
|
|
|
|
23. Sun Y, Yu X, Shi X, Hong W, Zhao J, Shi L. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. World J Surg Oncol. 2014 May;12:148. [CrossRef] |
|
|
|
|
|
24. Liang Z, Zhang J, Zeng X, Gao J, Wu S, Liu T. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer. 2010 Jan;10(1):376. [CrossRef] |
|
|
|
|
|
25. Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, et al. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012 Nov;118(11):2889-99. [CrossRef] |
|
|
|
|
|
26. Stenhouse G, Fyfe N, King G, Chapman A, Kerr KM. Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol. 2004 Apr;57(4):383-7. [CrossRef] |
|
|
|
|
|
27. Furukawa M, Toyooka S, Ichimura K, Yamamoto H, Soh J, Hashida S, et al. Genetic alterations in lung adenocarcinoma with a micropapillary component. Mol Clin Oncol. 2016;4(2):195-200. [CrossRef] |
|
Dragana Tegeltija;
Univerzitet u Novom Sadu, Medicinski fakultet, Novi Sad, Srbija;
+381 63 550 792;
This email address is being protected from spambots. You need JavaScript enabled to view it.;
This email address is being protected from spambots. You need JavaScript enabled to view it.